Overview Dividends

(MRK) Merck - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58933Y1055

Keytruda, Gardasil, Januvia, Bovilis, Bravecto

MRK EPS (Earnings per Share)

EPS Growth (3Y CAGR): 18.44%
EPS Trend (3Y Correlation): 44.1%

MRK Revenue

Revenue Growth (3Y CAGR): 8.43%
Revenue Trend (3Y Correlation): 76.9%

Risk via 10d forecast
Volatility	26.2%
Value at Risk 5%th	38.3%
Relative Tail Risk	-6.53%

Reward TTM
Sharpe Ratio	-0.07
Alpha	-10.00

Character TTM
Hurst Exponent	0.418
Beta	0.365
Beta Downside	0.482

Drawdowns 3y
Max DD	43.44%
Mean DD	15.40%
Median DD	10.57%

Description: MRK Merck September 24, 2025

Merck & Co., Inc. (ticker MRK) is a U.S.–based, globally operating healthcare company founded in 1891 and headquartered in Rahway, New Jersey, with business segments in human pharmaceuticals and animal health.

Its human-health portfolio spans oncology (Keytruda, Welireg, Zerbaxa, Noxafil), vaccines (Gardasil, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23), and chronic-disease therapies (Januvia/Janumet, Belsomra, Isentress, Adempas, Verquvo, Lagevrio, among others).

The animal-health division offers livestock products (Nuflor, Bovilis, Banamine, etc.) and companion-animal medicines (Bravecto, Sentinel, Nobivac, etc.), complemented by Allflex Livestock Intelligence digital solutions.

Merck maintains a network of strategic collaborations, including three deruxtecan ADC candidates with Daiichi Sankyo, co-development of Lynparza and Koselugo with AstraZeneca, licensing of the LM-299 bispecific antibody from LaNova, and partnerships with Eisai, Bayer, Ridgeback, Moderna, and Antengene to expand its oncology and immunotherapy pipeline.

Key financial and sector metrics: FY 2023 revenue reached approximately $59.3 billion, with Keytruda alone generating roughly $13 billion; R&D expenditure was about $9.5 billion (≈16 % of sales); animal health contributed ~ $5 billion. Primary growth drivers are an aging global population, rising cancer incidence, and sustained vaccine demand post-COVID-19, while pricing pressure in the U.S. and biosimilar competition pose ongoing risks.

For a deeper quantitative assessment of MRK’s valuation sensitivities and peer-adjusted multiples, the ValueRay platform offers a concise, data-driven dashboard worth exploring.

MRK Stock Overview

Market Cap in USD	214,149m
Sub-Industry	Pharmaceuticals
IPO / Inception	1978-01-13
Return 12m vs S&P 500	-14.5%
Analyst Rating	4.04 of 5

MRK Dividends

Dividend Yield	3.49%
Yield on Cost 5y	4.96%
Yield CAGR 5y	7.16%
Payout Consistency	97.7%
Payout Ratio	37.5%

MRK Growth Ratios

CAGR 3y	-0.85%
CAGR/Max DD Calmar Ratio	-0.02
CAGR/Mean DD Pain Ratio	-0.06
Current Volume	19632k
Average Volume	10758.9k

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (19.03b TTM) > 0 and > 6% of Revenue (6% = 3.85b TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA -0.89pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 29.47% (prev 17.06%; Δ 12.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 17.07b <= Net Income 19.03b (YES >=105%, WARN >=100%)

Net Debt (23.20b) to EBITDA (26.18b) ratio: 0.89 <= 3.0 (WARN <= 3.5)

Current Ratio 1.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (2.50b) change vs 12m ago -1.69% (target <= -2.0% for YES)

Gross Margin 78.32% (prev 75.82%; Δ 2.50pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 56.16% (prev 53.75%; Δ 2.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 13.53 (EBITDA TTM 26.18b / Interest Expense TTM 1.18b) >= 6 (WARN >= 3)

Altman Z'' 5.39

(A) 0.17 = (Total Current Assets 47.56b - Total Current Liabilities 28.63b) / Total Assets 111.21b

(B) 0.65 = Retained Earnings (Balance) 72.23b / Total Assets 111.21b

(D) 1.16 = Book Value of Equity 68.82b / Total Liabilities 59.36b

Total Rating: 5.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 86.41

1. Piotroski 6.50pt = 1.50

2. FCF Yield 5.50% = 2.75

3. FCF Margin 20.31% = 5.08

4. Debt/Equity 0.80 = 2.19

5. Debt/Ebitda 0.89 = 1.92

6. ROIC - WACC (= 10.17)% = 12.50

7. RoE 38.95% = 2.50

8. Rev. Trend 76.88% = 5.77

9. EPS Trend 44.06% = 2.20

What is the price of MRK shares?

As of November 15, 2025, the stock is trading at USD 92.92 with a total of 19,632,021 shares traded.
Over the past week, the price has changed by +7.70%, over one month by +9.70%, over three months by +13.39% and over the past year by -2.03%.

Is Merck a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Merck (NYSE:MRK) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 86.41 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRK is around 87.71 USD . This means that MRK is currently overvalued and has a potential downside of -5.61%.

Is MRK a buy, sell or hold?

Merck has received a consensus analysts rating of 4.04. Therefore, it is recommended to buy MRK.

Strong Buy: 12
Buy: 3
Hold: 11
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the MRK price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	101.5	9.3%
Analysts Target Price	101.5	9.3%
ValueRay Target Price	95.8	3.1%

MRK Fundamental Data Overview November 09, 2025

Market Cap USD = 214.15b (214.15b USD * 1.0 USD.USD)
P/E Trailing = 11.4127
P/E Forward = 9.1324
P/S = 3.3338
P/B = 4.5634
P/EG = 0.8012
Beta = 0.319
Revenue TTM = 64.23b USD
EBIT TTM = 16.02b USD
EBITDA TTM = 26.18b USD
Long Term Debt = 34.46b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.41b USD (from shortTermDebt, last quarter)
Debt = 41.37b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.20b USD (from netDebt column, last quarter)
Enterprise Value = 237.31b USD (214.15b + Debt 41.37b - CCE 18.21b)
Interest Coverage Ratio = 13.53 (Ebit TTM 16.02b / Interest Expense TTM 1.18b)
FCF Yield = 5.50% (FCF TTM 13.05b / Enterprise Value 237.31b)
FCF Margin = 20.31% (FCF TTM 13.05b / Revenue TTM 64.23b)
Net Margin = 29.63% (Net Income TTM 19.03b / Revenue TTM 64.23b)
Gross Margin = 78.32% ((Revenue TTM 64.23b - Cost of Revenue TTM 13.93b) / Revenue TTM)
Gross Margin QoQ = 81.92% (prev 77.50%)
Tobins Q-Ratio = 2.13 (Enterprise Value 237.31b / Total Assets 111.21b)
Interest Expense / Debt = 0.58% (Interest Expense 238.0m / Debt 41.37b)
Taxrate = 14.20% (958.0m / 6.75b)
NOPAT = 13.74b (EBIT 16.02b * (1 - 14.20%))
Current Ratio = 1.66 (Total Current Assets 47.56b / Total Current Liabilities 28.63b)
Debt / Equity = 0.80 (Debt 41.37b / totalStockholderEquity, last quarter 51.85b)
Debt / EBITDA = 0.89 (Net Debt 23.20b / EBITDA 26.18b)
Debt / FCF = 1.78 (Net Debt 23.20b / FCF TTM 13.05b)
Total Stockholder Equity = 48.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.11% (Net Income 19.03b / Total Assets 111.21b)
RoE = 38.95% (Net Income TTM 19.03b / Total Stockholder Equity 48.87b)
RoCE = 19.22% (EBIT 16.02b / Capital Employed (Equity 48.87b + L.T.Debt 34.46b))
RoIC = 16.43% (NOPAT 13.74b / Invested Capital 83.67b)
WACC = 6.26% (E(214.15b)/V(255.52b) * Re(7.37%) + D(41.37b)/V(255.52b) * Rd(0.58%) * (1-Tc(0.14)))
Discount Rate = 7.37% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.11%
[DCF Debug] Terminal Value 78.94% ; FCFE base≈13.77b ; Y1≈14.41b ; Y5≈16.75b
Fair Price DCF = 118.4 (DCF Value 293.77b / Shares Outstanding 2.48b; 5y FCF grow 5.00% → 3.0% )
EPS Correlation: 44.06 | EPS CAGR: 18.44% | SUE: 3.25 | # QB: 3
Revenue Correlation: 76.88 | Revenue CAGR: 8.43% | SUE: 0.60 | # QB: 0

Additional Sources for MRK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle